Celecoxib's Role in Preventing Bladder Cancer in Rats
Author Information
Author(s): José Sereno, Belmiro Parada, Flávio Reis, Cunha Fernanda X., Teixeira-Lemos Edite, Garrido Patrícia, Pinto Rui, Rocha-Pereira Petronila, Neto Paula, Ruivo José, Rodrigues-Santos Paulo, Nunes Sara, Mota Alfredo, Figueiredo Arnaldo, Teixeira Frederico
Primary Institution: Institute of Pharmacology & Experimental Therapeutics, Coimbra University
Hypothesis
Does celecoxib effectively prevent bladder cancer in a rat model when used preventively compared to curatively?
Conclusion
Preventive treatment with celecoxib significantly inhibits bladder cancer development, while curative treatment worsens tumor malignancy.
Supporting Evidence
- Preventive celecoxib treatment resulted in only 12.5% tumor incidence compared to 65% in the carcinogen group.
- The mean tumor volume in the preventive group was significantly lower at 5.3 mm3 compared to 112.5 mm3 in the carcinogen group.
- Curative treatment with celecoxib led to a 75% tumor incidence and increased tumor malignancy.
- Serum CRP levels were significantly lower in the celecoxib groups compared to the carcinogen group.
- Preventive treatment reduced hyperplasia and dysplasia incidence from 100% to 12.5%.
Takeaway
Giving celecoxib before cancer starts helps stop bladder cancer, but giving it after cancer has started can make it worse.
Methodology
The study used 52 male Wistar rats divided into five groups to evaluate the effects of celecoxib on bladder cancer.
Potential Biases
Potential bias in treatment administration and evaluation due to lack of blinding in some analyses.
Limitations
The study was conducted on a rat model, which may not fully replicate human bladder cancer.
Participant Demographics
52 male Wistar rats, aged 250-285g.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website